Atossa Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Atossa Therapeutics wird ein Gewinn- und Umsatzwachstum von 70.4% bzw. 71.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 69.8% pro Jahr wachsen soll.

Wichtige Informationen

70.4%

Wachstumsrate der Gewinne

69.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.2%
Wachstumsrate der Einnahmen	71.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	28 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Apr 26

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12

A First Assessment On Atossa Therapeutics

Dec 10

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 02

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Sep 22

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Jul 17

Atossa Therapeutics: Hope Springs Eternal

Jun 30

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Jun 16

Atossa reaches a two-year high ahead of data readout for breast cancer therapy

Jun 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Apr 02

Atossa updates on single-patient study for Endoxifen

Feb 04

Atossa halts Endoxifen breast cancer study after positive data

Feb 02

Atossa Therapeutics prices ~$25M direct offering, stock -23% PM

Jan 06

Atossa Therapeutics prices $14M registered direct offering

Dec 17

We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 10

Atossa Therapeutics plummets 38% after it raises $20M in public offering

Dec 09

Atossa Therapeutics EPS in-line

Nov 13

Safety data on COVID-19 nasal spray fails to lift Atossa, down 6%

Nov 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ATOS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	54	-2	-44	-43	3
12/31/2025	N/A	-36	-36	-30	4
12/31/2024	N/A	-30	-24	-26	4
3/31/2024	N/A	-30	-19	-19	N/A
12/31/2023	N/A	-30	-21	-21	N/A
9/30/2023	N/A	-30	-20	-20	N/A
6/30/2023	N/A	-32	-21	-21	N/A
3/31/2023	N/A	-28	-23	-23	N/A
12/31/2022	N/A	-27	-21	-21	N/A
9/30/2022	N/A	-24	-20	-20	N/A
6/30/2022	N/A	-21	-18	-18	N/A
3/31/2022	N/A	-22	-17	-17	N/A
12/31/2021	N/A	-21	-16	-16	N/A
9/30/2021	N/A	-28	-16	-16	N/A
6/30/2021	N/A	-26	-16	-16	N/A
3/31/2021	N/A	-23	-13	-13	N/A
12/31/2020	N/A	-22	-12	-12	N/A
9/30/2020	N/A	-13	-11	-11	N/A
6/30/2020	N/A	-13	-10	-10	N/A
3/31/2020	N/A	-16	-10	-10	N/A
12/31/2019	N/A	-17	-9	-9	N/A
9/30/2019	N/A	-17	-9	-9	N/A
6/30/2019	N/A	-17	-9	-9	N/A
3/31/2019	N/A	-25	-9	-9	N/A
12/31/2018	N/A	-23	-9	-9	N/A
9/30/2018	N/A	-23	-8	-8	N/A
6/30/2018	N/A	-22	-8	-8	N/A
3/31/2018	N/A	-11	-7	-7	N/A
12/31/2017	N/A	-11	N/A	-7	N/A
9/30/2017	N/A	-11	N/A	-6	N/A
6/30/2017	N/A	-9	N/A	-4	N/A
3/31/2017	N/A	-6	N/A	-4	N/A
12/31/2016	N/A	-6	N/A	-5	N/A
9/30/2016	0	-6	N/A	-8	N/A
6/30/2016	0	-10	N/A	-12	N/A
3/31/2016	0	-12	N/A	-14	N/A
12/31/2015	0	-13	N/A	-14	N/A
9/30/2015	0	-13	N/A	-13	N/A
6/30/2015	0	-13	N/A	-12	N/A
3/31/2015	0	-13	N/A	-11	N/A
12/31/2014	0	-12	N/A	-11	N/A
9/30/2014	0	-12	N/A	-10	N/A
6/30/2014	0	-12	N/A	-10	N/A
3/31/2014	0	-11	N/A	-10	N/A
12/31/2013	1	-11	N/A	-9	N/A
9/30/2013	1	-10	N/A	-8	N/A
6/30/2013	1	-7	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ATOS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: ATOS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ATOS wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ATOS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ATOS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ATOS in 3 Jahren voraussichtlich hoch sein wird

Atossa Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2026

Price target decreased by 7.5% to US$4.63

Price target decreased to US$5.00

Price target decreased to US$5.00

Recent updates

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

No longer forecast to breakeven

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

No longer forecast to breakeven

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

New minor risk - Profitability

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient

New minor risk - Share price stability

Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Forecast to breakeven in 2026

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Atossa Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics, Inc. Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

New minor risk - Share price stability

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) announces an Equity Buyback for $10 million worth of its shares.

Atossa Therapeutics, Inc. Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Announces Executive Changes

Price target decreased by 7.5% to US$4.63

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Price target decreased to US$5.00

Price target decreased to US$5.00

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. Appoints Richard Graydon as Interim Chief Medical Officer

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate Its Phase 2 Study of Neoadjuvant (Z)-Endoxifen in Premenopausal Women with Er+/Her2- Breast Cancer

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Atossa Therapeutics Receives Letter from NASDAQ Regarding Minimum Bid Price Requirement

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics, Inc. Appoints Dr. Paul Wabnitz to its Scientific Advisory Board

Atossa Therapeutics GAAP EPS of -$0.05

Atossa Therapeutics, Inc. Announces Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Insufficient new directors

Atossa Therapeutics, Inc. Announces Completion of Participants Enrollment in Part B of its Phase 1/2a Clinical Study of AT-H201 in Australia, Consisting of Multiple Ascending Dose Cohorts in Healthy Participants

Atossa Therapeutics, Inc., Annual General Meeting, May 13, 2022

No longer forecast to breakeven

Price target decreased to US$6.38

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Forecast to breakeven in 2024

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

A First Assessment On Atossa Therapeutics

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Atossa Therapeutics Receives Approval from Swedish Ethics Review Authority to Initiate A Phase 2 Clinical Study of Oral Endoxifen

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Independent Director notifies of intention to sell stock

Atossa Therapeutics: Hope Springs Eternal

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density

Price target increased to US$7.50

Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated

Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery At A Webinar At 8 Am Pacific Time on June 9, 2021